What is cTIV+PV OR eTIV_a+PV used for?

cTIV+PV OR eTIV_a+PV is indicated for Investigational treatment for various conditions.

Who makes cTIV+PV OR eTIV_a+PV?

cTIV+PV OR eTIV_a+PV is developed by Novartis.

What development phase is cTIV+PV OR eTIV_a+PV in?

cTIV+PV OR eTIV_a+PV is in Phase 3.

Last reviewed 2026-04-23 · How we verify

cTIV+PV OR eTIV_a+PV

Novartis · Phase 3 active Biologic

cTIV+PV and eTIV_a+PV are investigational drugs with unknown mechanisms of action.

cTIV+PV and eTIV_a+PV are investigational drugs with unknown mechanisms of action. Used for Investigational treatment for various conditions.

At a glance

Generic name	cTIV+PV OR eTIV_a+PV
Sponsor	Novartis
Modality	Biologic
Phase	Phase 3

Mechanism of action

Further research is needed to understand how these drugs work mechanistically.

Approved indications

Investigational treatment for various conditions

Common side effects

No common side effects on file.

Key clinical trials

Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

cTIV+PV OR eTIV_a+PV CI brief — competitive landscape report
cTIV+PV OR eTIV_a+PV updates RSS · CI watch RSS
Novartis portfolio CI